These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32678687)

  • 41. New vehicle based on a microemulsion for topical ocular administration of dexamethasone.
    Fialho SL; da Silva-Cunha A
    Clin Exp Ophthalmol; 2004 Dec; 32(6):626-32. PubMed ID: 15575833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Coated particle assemblies for the concomitant pulmonary administration of budesonide and salbutamol sulphate.
    Raula J; Rahikkala A; Halkola T; Pessi J; Peltonen L; Hirvonen J; Järvinen K; Laaksonen T; Kauppinen EI
    Int J Pharm; 2013 Jan; 441(1-2):248-54. PubMed ID: 23200957
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
    Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
    Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Self Nanoemulsifying Drug Delivery System of Sorafenib Tosylate: Development and
    Sandhya P; Poornima P; Bhikshapathi DVRN
    Pharm Nanotechnol; 2020; 8(6):471-484. PubMed ID: 33069205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative bioequivalence study of two marketed formulation of betamethasone injectable suspensions.
    Zakeri-Milani P; Ghanbarzadeh S; Basmenji S; Valizadeh H
    Drug Res (Stuttg); 2013 Oct; 63(10):545-9. PubMed ID: 23780505
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative bioavailability study of cefixime (equivalent to 100 mg/5 ml) suspension (Winex vs Suprax) in healthy male volunteers.
    Asiri YA; Al-Said MS; Al-Khamis KI; Niazy EM; El-Sayed YM; Al-Rashood KA; Al-Yamani MJ; Alsarra IA; Al-Balla SA
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):499-504. PubMed ID: 16240707
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preparation and characterization of fast dissolving pullulan films containing BCS class II drug nanoparticles for bioavailability enhancement.
    Krull SM; Ma Z; Li M; Davé RN; Bilgili E
    Drug Dev Ind Pharm; 2016; 42(7):1073-85. PubMed ID: 26567632
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Physiologically Based Pharmacokinetic Model to Support Ophthalmic Suspension Product Development.
    Le Merdy M; Tan ML; Babiskin A; Zhao L
    AAPS J; 2020 Jan; 22(2):26. PubMed ID: 31907674
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone.
    Daley-Yates PT; Gregory AJ; Brooks CD
    Br J Clin Pharmacol; 1997 Jun; 43(6):593-601. PubMed ID: 9205819
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Budesonide quantification by HPLC coupled to atmospheric pressure photoionization (APPI) tandem mass spectrometry. Application to a comparative systemic bioavailability of two budesonide formulations in healthy volunteers.
    Borges NC; Astigarraga RB; Sverdloff CE; Borges BC; Paiva TR; Galvinas PR; Moreno RA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Feb; 879(3-4):236-42. PubMed ID: 21233029
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel nanocrystal-based solid dispersion with high drug loading, enhanced dissolution, and bioavailability of andrographolide.
    Ma Y; Yang Y; Xie J; Xu J; Yue P; Yang M
    Int J Nanomedicine; 2018; 13():3763-3779. PubMed ID: 29988798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability.
    Yang H; Teng F; Wang P; Tian B; Lin X; Hu X; Zhang L; Zhang K; Zhang Y; Tang X
    Int J Pharm; 2014 Dec; 477(1-2):88-95. PubMed ID: 25455766
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physiochemical properties and low oral bioavailability.
    Singh MK; Pooja D; Ravuri HG; Gunukula A; Kulhari H; Sistla R
    Phytomedicine; 2018 Feb; 40():48-54. PubMed ID: 29496174
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preparation of an oil suspension containing ondansetron hydrochloride as a sustained release parenteral formulation.
    Nguyen TT; Duong VA; Maeng HJ; Chi SC
    Drug Deliv Transl Res; 2020 Feb; 10(1):282-295. PubMed ID: 31659599
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers.
    Liu J; Zhou X
    Int J Clin Pharmacol Ther; 2014 Feb; 52(2):175-80. PubMed ID: 24424109
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single-Dose Pharmacokinetic Properties and Relative Bioavailability of Different Formulations of Posaconazole Oral Suspension in Healthy Volunteers.
    Vuletić L; Herceg M; Ferderber K; Tunjić I; Rizea-Savu S; Duna SN; Cetina-Čižmek B; Filipović-Grčić J
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):827-836. PubMed ID: 30536797
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts.
    Kador PF; Randazzo J; Babb T; Koushik K; Takamura Y; Zhu W; Blessing K; Kompella UB
    J Ocul Pharmacol Ther; 2007 Apr; 23(2):116-23. PubMed ID: 17444799
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort
    Gillen M; Forte P; Svensson JO; Lamarca R; Burke J; Rask K; Larsdotter Nilsson U; Eckerwall G
    Pulm Pharmacol Ther; 2018 Oct; 52():7-17. PubMed ID: 30077809
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preparation, characterization and pharmacokinetics of cyadox nanosuspension.
    Sattar A; Chen D; Jiang L; Pan Y; Tao Y; Huang L; Liu Z; Xie S; Yuan Z
    Sci Rep; 2017 May; 7(1):2289. PubMed ID: 28536446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.